Alkermes plc
(NASDAQ:ALKS)
$25.75
-0.08 (-0.31%)
At Close: 4:00 PM
$25.75
0.00 (0.00%)
After Market: 7:40 PM
Alkermes Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
Alkermes Stock Price Today
Alkermes plc (ALKS) stock declined over -0.31% intraday to trade at $25.75 a share on NASDAQ. The stock opened with a gain of 0.58% at $25.98 and touched an intraday high of $26.15, falling -0.31% against the last close of $25.83. The Alkermes plc in stock market went to a low of $25.43 during the session.
Alkermes Stock Snapshot
$25.83
Prev. Close
4.34 Billion
Market Cap
$25.43
Day Low
$25.98
Open
163.54 Million
Number of Shares
$26.15
Day High
-
P/E ratio
-0.97
EPS (TTM)
3.53
Cash Flow per Share
5.56
Free Float in %
6.56
Book Value
867,371
Volume
Contact Details
Connaught House
1 Burlington Road
Dublin 4
Ireland
Website:https://www.alkermes.com
Contact #:353 1 772 8000
Company Information
Employees2,280
Beta0.61
Sales or Revenue$1.13 Billion
5Y Sales Change4.20%
Fiscal Year EndsDec. 2021
SectorHealth Care
IndustryBiotechnology
About Company
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Frequently Asked Questions
What is the current Alkermes plc (ALKS) stock price?
Alkermes plc (NASDAQ: ALKS) stock price is $25.75 in the last trading session. During the trading session, ALKS stock reached the peak price of $26.15 while $25.43 was the lowest point it dropped to. The percentage change in ALKS stock occurred in the recent session was -0.31% while the dollar amount for the price change in ALKS stock was -$0.08.
ALKS's industry and sector of operation?
The NASDAQ listed ALKS is part of Biotechnology industry that operates in the broader Health Care sector. Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
Who are the executives of ALKS?
Mr. Michael J. Landine
Senior Vice President of Corporation Devel. & Chief Risk Officer
Mr. Blair C. Jackson
Executive Vice President & Chief Operating Officer
Dr. Craig C. Hopkinson M.D.
Executive Vice President of R&D and Chief Medical Officer
Mr. Thomas Harvey
Chief Information Officer & Senior Vice President of IT
How ALKS did perform over past 52-week?
ALKS's closing price is 0.18% higher than its 52-week low of $21.75 where as its distance from 52-week high of $32.79 is -0.21%.
How many employees does ALKS have?
Number of ALKS employees currently stands at 2,280. ALKS operates from Connaught House, 1 Burlington Road, Dublin 4, Ireland.
Link for ALKS official website?
Official Website of ALKS is: https://www.alkermes.com
How do I contact ALKS?
ALKS could be contacted at phone #353 1 772 8000 and can also be accessed through its website. ALKS operates from Connaught House, 1 Burlington Road, Dublin 4, Ireland.
How many shares of ALKS are traded daily?
ALKS stock volume for the day was 867,371 shares. The average number of ALKS shares traded daily for last 3 months was 1.26 Million.
What is the market cap of ALKS currently?
The market value of ALKS currently stands at $4.34 Billion with its latest stock price at $25.75 and 163.54 Million of its shares outstanding.